Chris Daige, MS, DABT

Chris Daige, MS, DABT has extensive work experience in the pharmaceutical and biotechnology industry. Starting in 2000, Chris worked as a Research Associate at X-Ceptor Therapeutics for four years. Chris then joined Exelixis as an Associate Research Scientist from 2004 to 2007. Following this, Chris worked at Kalypsys as a Scientist I from 2007 to 2009. Chris then joined Regulus Therapeutics as an Associate in 2009 before moving to Mirna Therapeutics, Inc. as a Senior Scientist/Manager from 2010 to 2016. From 2017 to 2022, Chris held roles at Aeglea BioTherapeutics, starting as a Director of Biology and Toxicology and later becoming a Senior Director. Currently, Chris serves as the Senior Director of Nonclinical Development at Aditum Bio.

Chris Daige, MS, DABT has a Master of Science (MS) degree in Bioinformatics from the University of Maryland Global Campus. The duration of the degree program was from 2006 to 2010. Additionally, there is no available information about the duration or specific field of study for their education at the University of Vermont. Chris Daige also holds additional certifications including an Effective Organizational Communication certificate from Harvard University obtained in May 2023, and a DABT (Diplomate of the American Board of Toxicology) certification obtained in 2018 from the American Board of Toxicology, Inc.